NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.95 +0.35 (+2.11 %)
(As of 05/23/2018 03:19 PM ET)
Previous Close$17.00
Today's Range$16.80 - $17.35
52-Week Range$11.90 - $20.40
Volume8,629 shs
Average Volume535,884 shs
Market Capitalization$862.43 million
P/E Ratio-49.29
Dividend YieldN/A
Beta1.12

About Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals logoVanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its products also include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; VTR-297, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and VQW-765, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. In addition, the company is developing cystic fibrosis transmembrane conductance regulator activators and inhibitors. It markets its products in the United States, Canada, Europe, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Receive VNDA News and Ratings via Email

Sign-up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:VNDA
CUSIP92165910
Phone202-734-3400

Debt

Debt-to-Equity RatioN/A
Current Ratio3.93
Quick Ratio3.91

Price-To-Earnings

Trailing P/E Ratio-49.29
Forward P/E Ratio-339.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$165.08 million
Price / Sales5.35
Cash FlowN/A
Price / CashN/A
Book Value$4.63 per share
Price / Book3.66

Profitability

EPS (Most Recent Fiscal Year)($0.35)
Net Income$-15,560,000.00
Net Margins-2.84%
Return on Equity-3.06%
Return on Assets-2.07%

Miscellaneous

Employees273
Outstanding Shares52,110,000

Vanda Pharmaceuticals (NASDAQ:VNDA) Frequently Asked Questions

What is Vanda Pharmaceuticals' stock symbol?

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) announced its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported $0.06 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.23. The biopharmaceutical company earned $43.59 million during the quarter, compared to the consensus estimate of $43.30 million. Vanda Pharmaceuticals had a negative net margin of 2.84% and a negative return on equity of 3.06%. The company's quarterly revenue was up 16.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.11) EPS. View Vanda Pharmaceuticals' Earnings History.

When is Vanda Pharmaceuticals' next earnings date?

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for Vanda Pharmaceuticals.

What price target have analysts set for VNDA?

6 brokerages have issued 12 month price targets for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $27.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $23.00 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Who are some of Vanda Pharmaceuticals' key competitors?

Who are Vanda Pharmaceuticals' key executives?

Vanda Pharmaceuticals' management team includes the folowing people:
  • Dr. Mihael H. Polymeropoulos, Founder, Pres, CEO & Director (Age 58)
  • Mr. James Patrick Kelly, Exec. VP, CFO, Treasurer & Sec. (Age 52)
  • Mr. Gunther Birznieks, Sr. VP of Bus. Devel. (Age 49)
  • Mr. Gian Piero Reverberi, Sr. VP & Chief Commercial Officer (Age 52)
  • Dr. Deepak Phadke Ph.D., VP of Manufacturing (Age 68)

Has Vanda Pharmaceuticals been receiving favorable news coverage?

Press coverage about VNDA stock has trended somewhat positive on Wednesday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Vanda Pharmaceuticals earned a coverage optimism score of 0.06 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.30 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (8.19%), venBio Select Advisor LLC (5.33%), Rothschild Asset Management Inc. (2.60%), Millennium Management LLC (1.91%), Prudential Financial Inc. (1.63%) and Northern Trust Corp (1.12%). Company insiders that own Vanda Pharmaceuticals stock include Gunther Birznieks, James E Flynn, James Patrick Kelly, Mihael Hristos Polymeropoulos and Richard L Gulino. View Institutional Ownership Trends for Vanda Pharmaceuticals.

Which major investors are selling Vanda Pharmaceuticals stock?

VNDA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., PNC Financial Services Group Inc., Millennium Management LLC, Spark Investment Management LLC, Cortina Asset Management LLC, Schwab Charles Investment Management Inc., JPMorgan Chase & Co. and Wells Fargo & Company MN. Company insiders that have sold Vanda Pharmaceuticals company stock in the last year include Gunther Birznieks, James Patrick Kelly and Mihael Hristos Polymeropoulos. View Insider Buying and Selling for Vanda Pharmaceuticals.

Which major investors are buying Vanda Pharmaceuticals stock?

VNDA stock was bought by a variety of institutional investors in the last quarter, including venBio Select Advisor LLC, Hawk Ridge Capital Management LP, Alambic Investment Management L.P., Prudential Financial Inc., A.R.T. Advisors LLC, Russell Investments Group Ltd., UBS Group AG and Swiss National Bank. View Insider Buying and Selling for Vanda Pharmaceuticals.

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vanda Pharmaceuticals' stock price today?

One share of VNDA stock can currently be purchased for approximately $16.95.

How big of a company is Vanda Pharmaceuticals?

Vanda Pharmaceuticals has a market capitalization of $862.43 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

How can I contact Vanda Pharmaceuticals?

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE N.W. SUITE 300 E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]


MarketBeat Community Rating for Vanda Pharmaceuticals (VNDA)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  324 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  481
MarketBeat's community ratings are surveys of what our community members think about Vanda Pharmaceuticals and other stocks. Vote "Outperform" if you believe VNDA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VNDA will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Vanda Pharmaceuticals (NASDAQ:VNDA) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
6 Wall Street analysts have issued ratings and price targets for Vanda Pharmaceuticals in the last 12 months. Their average twelve-month price target is $23.00, suggesting that the stock has a possible upside of 35.69%. The high price target for VNDA is $27.00 and the low price target for VNDA is $18.00. There are currently 6 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.00$22.40$22.00$22.20
Price Target Upside: 35.69% upside31.61% upside38.80% upside68.82% upside

Vanda Pharmaceuticals (NASDAQ:VNDA) Consensus Price Target History

Price Target History for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/23/2018CitigroupInitiated CoverageBuy$26.00HighView Rating Details
5/3/2018OppenheimerSet Price TargetBuy$27.00HighView Rating Details
2/28/2018Seaport Global SecuritiesReiterated RatingBuy$21.00LowView Rating Details
2/13/2018Jefferies GroupReiterated RatingBuy$20.00LowView Rating Details
10/19/2017Piper Jaffray CompaniesSet Price TargetBuy$26.00N/AView Rating Details
8/3/2017HC WainwrightSet Price TargetBuy$18.00HighView Rating Details
4/12/2017CIBCReiterated RatingOutperform ➝ Outperform$21.00LowView Rating Details
11/9/2016AegisInitiated CoverageBuy$24.00N/AView Rating Details
10/10/2016Brean CapitalSet Price TargetBuy$24.00N/AView Rating Details
8/26/2016JMP SecuritiesBoost Price TargetMarket Outperform$18.00 ➝ $22.00N/AView Rating Details
(Data available from 5/23/2016 forward)

Earnings

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings History and Estimates Chart

Earnings by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ:VNDA) Earnings Estimates

2018 EPS Consensus Estimate: ($0.20)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.12)($0.03)($0.08)
Q2 20183($0.06)$0.02($0.01)
Q3 20183($0.57)$0.07($0.16)
Q4 20183($0.06)$0.12$0.06

Vanda Pharmaceuticals (NASDAQ VNDA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.32)N/AView Earnings Details
5/2/2018Q1 2018($0.17)$0.06$43.30 million$43.59 millionViewListenView Earnings Details
2/14/2018Q4 2017($0.12)($0.04)$44.00 million$44.28 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.10)($0.10)$43.90 million$41.30 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.21)($0.03)$40.31 million$42.06 millionViewListenView Earnings Details
5/2/2017Q1 2017($0.13)($0.17)$38.35 million$37.42 millionViewListenView Earnings Details
2/15/2017Q416($0.06)($0.01)$39.38 million$38.24 millionViewListenView Earnings Details
11/2/2016Q316($0.14)($0.01)$38.05 million$38.48 millionViewListenView Earnings Details
7/27/2016Q216($0.23)($0.11)$36.03 million$36.02 millionViewListenView Earnings Details
5/4/2016Q116($0.24)($0.17)$32.48 million$33.30 millionViewListenView Earnings Details
2/10/2016Q415($0.26)($0.23)$31.34 million$31.85 millionViewListenView Earnings Details
11/3/2015Q315($0.20)($0.11)$28.58 million$28.34 millionViewListenView Earnings Details
7/29/2015Q2($0.32)($0.01)$24.55 million$27.60 millionViewListenView Earnings Details
5/6/2015Q1($0.25)($0.24)$20.18 million$22.20 millionViewListenView Earnings Details
2/19/2015Q4$0.56($0.36)$35.57 million$15.40 millionViewListenView Earnings Details
10/27/2014Q314($0.39)($0.04)$12.20 million$14.80 millionViewListenView Earnings Details
8/7/2014Q2($0.70)($0.64)$10.00 million$10.80 millionViewListenView Earnings Details
5/8/2014Q1($0.29)($0.79)$8.50 million$9.10 millionViewListenView Earnings Details
2/13/2014Q413($0.20)($0.23)$8.50 million$8.80 millionViewListenView Earnings Details
11/7/2013Q313($0.30)($0.43)$8.45 million$8.70 millionViewListenView Earnings Details
7/31/2013Q2 2013($0.22)($0.26)$8.43 million$8.30 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.25)($0.15)$8.42 million$8.10 millionViewListenView Earnings Details
2/12/2013Q4 2012($0.22)($0.23)$8.60 million$7.90 millionViewListenView Earnings Details
11/7/2012Q312($0.22)($0.19)$8.40 million$8.28 millionViewN/AView Earnings Details
8/2/2012($0.27)($0.28)ViewN/AView Earnings Details
5/8/2012($0.16)($0.28)ViewN/AView Earnings Details
2/14/2012($0.19)($0.20)ViewN/AView Earnings Details
11/4/2011($0.12)($0.11)ViewN/AView Earnings Details
8/4/2011($0.07)($0.05)ViewN/AView Earnings Details
2/10/2011($0.02)$0.08ViewN/AView Earnings Details
11/3/2010Q3 2010$0.03$0.11ViewN/AView Earnings Details
8/5/2010Q2 2010$0.10$0.04ViewN/AView Earnings Details
5/4/2010Q1 2010$0.06$0.02ViewN/AView Earnings Details
2/16/2010Q4 2009($0.25)($0.34)ViewN/AView Earnings Details
11/2/2009Q3 2009($0.30)($0.28)ViewN/AView Earnings Details
8/10/2009Q2 2009($0.26)($0.46)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.22)($0.24)ViewN/AView Earnings Details
2/11/2009Q4 2008($0.42)($0.28)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.44)($0.41)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.70)($0.51)ViewN/AView Earnings Details
5/1/2008Q1 2008($0.86)($0.72)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.76)($0.78)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Vanda Pharmaceuticals (NASDAQ:VNDA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.80%
Institutional Ownership Percentage: 90.40%
Insider Trading History for Vanda Pharmaceuticals (NASDAQ:VNDA)
Institutional Ownership by Quarter for Vanda Pharmaceuticals (NASDAQ:VNDA)

Vanda Pharmaceuticals (NASDAQ VNDA) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/1/2018Gunther BirznieksSVPSell8,525$18.72$159,588.00148,366View SEC Filing  
3/1/2018James Patrick KellyCFOSell8,532$18.72$159,719.04208,066View SEC Filing  
3/1/2018Mihael Hristos PolymeropoulosInsiderSell60,966$18.72$1,141,283.521,243,838View SEC Filing  
1/2/2018Gunther BirznieksSVPSell8,568$15.26$130,747.68118,366View SEC Filing  
1/2/2018James Patrick KellyCFOSell9,155$15.35$140,529.25144,721View SEC Filing  
1/2/2018Mihael Hristos PolymeropoulosInsiderSell191,760$15.30$2,933,928.001,031,848View SEC Filing  
1/3/2017Richard L GulinoSVPSell10,900$15.51$169,059.0012,500View SEC Filing  
9/23/2016James E FlynnInsiderSell1,120,461$16.56$18,554,834.16View SEC Filing  
9/19/2016James E FlynnInsiderSell547,886$15.66$8,579,894.76View SEC Filing  
1/4/2016James Patrick KellyCFOSell9,564$8.96$85,693.4460,772View SEC Filing  
1/4/2016Mihael Hristos PolymeropoulosCEOSell21,353$8.96$191,322.88839,178View SEC Filing  
1/4/2016Paolo BaroldiSVPSell12,380$8.96$110,924.8040,665View SEC Filing  
12/11/2015James E FlynnInsiderBuy1,201,364$8.38$10,067,430.32View SEC Filing  
9/10/2015Mihael Hristos PolymeropoulosCEOSell131,739$12.68$1,670,450.52816,781View SEC Filing  
5/22/2015Mihael Hristos PolymeropoulosCEOSell186,395$10.36$1,931,052.20View SEC Filing  
3/9/2015Richard W DuganDirectorSell4,804$10.69$51,354.76View SEC Filing  
12/23/2014James E FlynnInsiderBuy162,014$14.40$2,333,001.60View SEC Filing  
3/14/2014Thomas WatkinsDirectorSell35,000$17.66$618,100.00View SEC Filing  
11/21/2013Robert RepellaSVPSell107,500$12.03$1,293,225.0015,000View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Vanda Pharmaceuticals (NASDAQ VNDA) News Headlines

Source:
DateHeadline
Vanda Pharmaceuticals (VNDA) Coverage Initiated by Analysts at CitigroupVanda Pharmaceuticals (VNDA) Coverage Initiated by Analysts at Citigroup
www.americanbankingnews.com - May 23 at 12:45 PM
Vanda Pharmaceuticals (VNDA) Says HETLIOZ Effective in Treating Jet Lag during Transatlantic TravelVanda Pharmaceuticals (VNDA) Says HETLIOZ Effective in Treating Jet Lag during Transatlantic Travel
www.streetinsider.com - May 23 at 9:23 AM
BRIEF-Vanda Pharmaceuticals Says Hetlioz Is Effective In Treating Jet Lag During Transatlantic TravelBRIEF-Vanda Pharmaceuticals Says Hetlioz Is Effective In Treating Jet Lag During Transatlantic Travel
www.reuters.com - May 23 at 9:23 AM
HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic TravelHETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
finance.yahoo.com - May 23 at 9:23 AM
Vanda Pharmaceuticals (VNDA) Upgraded to "Buy" at BidaskClubVanda Pharmaceuticals (VNDA) Upgraded to "Buy" at BidaskClub
www.americanbankingnews.com - May 17 at 5:47 PM
Vanda Pharmaceuticals Inc. (VNDA) Given Consensus Recommendation of "Buy" by AnalystsVanda Pharmaceuticals Inc. (VNDA) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 17 at 1:32 PM
$47.17 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$47.17 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - May 15 at 4:26 AM
Zacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) to Announce $0.02 EPSZacks: Brokerages Expect Vanda Pharmaceuticals Inc. (VNDA) to Announce $0.02 EPS
www.americanbankingnews.com - May 13 at 5:25 AM
Vanda Pharmaceuticals (VNDA) Upgraded to Buy at ValuEngineVanda Pharmaceuticals (VNDA) Upgraded to Buy at ValuEngine
www.americanbankingnews.com - May 12 at 10:39 AM
Vanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare Conference - SlideshowVanda Pharmaceuticals (VNDA) Presents At 43rd annual Deutsche Bank Healthcare Conference - Slideshow
seekingalpha.com - May 10 at 4:17 PM
Vanda Pharmaceuticals (VNDA) Downgraded to "Hold" at Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 10 at 3:06 PM
Vanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care ConferenceVanda Pharmaceuticals to Present at the Deutsche Bank 43rd Annual Health Care Conference
finance.yahoo.com - May 7 at 10:11 AM
First Week of VNDA December 21st Options TradingFirst Week of VNDA December 21st Options Trading
www.nasdaq.com - May 5 at 9:58 AM
Vanda Pharmaceuticals (VNDA) PT Set at $27.00 by OppenheimerVanda Pharmaceuticals (VNDA) PT Set at $27.00 by Oppenheimer
www.americanbankingnews.com - May 4 at 7:02 PM
Heres Why Vanda Pharmaceuticals Shares Are Flying Higher TodayHere's Why Vanda Pharmaceuticals' Shares Are Flying Higher Today
www.fool.com - May 4 at 4:18 PM
Vanda Pharmaceuticals (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - Earnings Call TranscriptVanda Pharmaceuticals' (VNDA) CEO Mihael Polymeropoulos on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:38 AM
Vanda: 1Q Earnings SnapshotVanda: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:38 AM
Edited Transcript of VNDA earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of VNDA earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 9:38 AM
Vanda Pharmaceuticals (VNDA) Announces Quarterly  Earnings Results, Beats Expectations By $0.31 EPSVanda Pharmaceuticals (VNDA) Announces Quarterly Earnings Results, Beats Expectations By $0.31 EPS
www.americanbankingnews.com - May 2 at 9:44 PM
Vanda Pharmaceuticals Reports First Quarter 2018 Financial ResultsVanda Pharmaceuticals Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 4:16 PM
Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?Madrigal (MDGL) Q1 Earnings: Disappointment in the Cards?
www.msn.com - May 1 at 4:13 PM
AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?AVEO Pharmaceuticals (AVEO) Q1 Earnings: What's in Store?
finance.yahoo.com - April 30 at 10:42 AM
Vanda Pharmaceuticals (VNDA) Lowered to "Hold" at BidaskClubVanda Pharmaceuticals (VNDA) Lowered to "Hold" at BidaskClub
www.americanbankingnews.com - April 27 at 11:56 AM
Vanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $43.40 MillionVanda Pharmaceuticals Inc. (VNDA) Expected to Post Quarterly Sales of $43.40 Million
www.americanbankingnews.com - April 27 at 2:20 AM
 Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Earnings of -$0.05 Per Share Analysts Anticipate Vanda Pharmaceuticals Inc. (VNDA) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - April 25 at 5:10 PM
Vanda Pharmaceuticals (VNDA) Scheduled to Post Quarterly Earnings on WednesdayVanda Pharmaceuticals (VNDA) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 3:34 AM
Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?Vanda Pharmaceuticals Inc. (VNDA) Sees Hammer Chart Pattern: Time to Buy?
finance.yahoo.com - April 24 at 9:42 AM
Vanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from BrokeragesVanda Pharmaceuticals Inc. (VNDA) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 22 at 9:30 AM
Vanda Pharmaceuticals (VNDA) Rating Increased to Buy at Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 20 at 11:54 AM
Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018Vanda Pharmaceuticals to Announce First Quarter 2018 Financial Results on May 2, 2018
finance.yahoo.com - April 19 at 9:59 AM
Vanda Pharmaceuticals (VNDA) Downgraded by Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 3:34 PM
Patent on Vanda schizophrenia drug upheld by appeals courtPatent on Vanda schizophrenia drug upheld by appeals court
www.reuters.com - April 15 at 4:22 PM
Vanda Pharmaceuticals (VNDA) Says It Won Case on FanaptVanda Pharmaceuticals (VNDA) Says It Won Case on Fanapt
www.streetinsider.com - April 15 at 4:22 PM
Vanda Pharmaceuticals Inc. (VNDA) Sees Significant Decline in Short InterestVanda Pharmaceuticals Inc. (VNDA) Sees Significant Decline in Short Interest
www.americanbankingnews.com - April 15 at 1:14 AM
Vanda Pharmaceuticals (VNDA) Given a $21.00 Price Target at OppenheimerVanda Pharmaceuticals (VNDA) Given a $21.00 Price Target at Oppenheimer
www.americanbankingnews.com - April 13 at 8:19 PM
Vanda Pharmaceuticals (VNDA) Given a $18.00 Price Target by HC Wainwright AnalystsVanda Pharmaceuticals (VNDA) Given a $18.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 13 at 7:15 PM
Vanda Pharmaceuticals (VNDA) PT Set at $23.00 by Piper JaffrayVanda Pharmaceuticals (VNDA) PT Set at $23.00 by Piper Jaffray
www.americanbankingnews.com - April 13 at 5:29 PM
Vanda Wins Appeal Case on Fanapt®Vanda Wins Appeal Case on Fanapt®
finance.yahoo.com - April 13 at 4:15 PM
Vanda Pharmaceuticals (VNDA) Lifted to Strong-Buy at Zacks Investment ResearchVanda Pharmaceuticals (VNDA) Lifted to Strong-Buy at Zacks Investment Research
www.americanbankingnews.com - April 12 at 7:25 PM
Vanda Pharmaceuticals Target of Unusually High Options Trading (VNDA)Vanda Pharmaceuticals Target of Unusually High Options Trading (VNDA)
www.americanbankingnews.com - April 11 at 7:04 AM
$43.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter$43.40 Million in Sales Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - April 10 at 2:23 AM
Vanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic DermatitisVanda to Present Tradipitant Scientific Posters at the 10th Georg Rajka International Symposium of Atopic Dermatitis
finance.yahoo.com - April 9 at 4:16 PM
Jefferies Group Analysts Cut Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)Jefferies Group Analysts Cut Earnings Estimates for Vanda Pharmaceuticals Inc. (VNDA)
www.americanbankingnews.com - April 9 at 2:28 AM
-$0.09 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter-$0.09 Earnings Per Share Expected for Vanda Pharmaceuticals Inc. (VNDA) This Quarter
www.americanbankingnews.com - April 8 at 7:10 PM
Vanda Pharmaceuticals (VNDA) Lowered to Sell at ValuEngineVanda Pharmaceuticals (VNDA) Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 4 at 6:23 PM
Oppenheimer Analysts Give Vanda Pharmaceuticals (VNDA) a $26.00 Price TargetOppenheimer Analysts Give Vanda Pharmaceuticals (VNDA) a $26.00 Price Target
www.americanbankingnews.com - April 4 at 3:32 PM
Vanda Pharmaceuticals (VNDA) Rating Lowered to Sell at ValuEngineVanda Pharmaceuticals (VNDA) Rating Lowered to Sell at ValuEngine
www.americanbankingnews.com - March 31 at 11:34 PM
Oppenheimer Reiterates "Buy" Rating for Vanda Pharmaceuticals (VNDA)Oppenheimer Reiterates "Buy" Rating for Vanda Pharmaceuticals (VNDA)
www.americanbankingnews.com - March 30 at 1:48 PM
Vanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from AnalystsVanda Pharmaceuticals Inc. (VNDA) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - March 28 at 9:44 AM
Vanda receives notice of Teva application for generic HetliozVanda receives notice of Teva application for generic Hetlioz
seekingalpha.com - March 26 at 4:19 PM

SEC Filings

Vanda Pharmaceuticals (NASDAQ:VNDA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Vanda Pharmaceuticals (NASDAQ:VNDA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Vanda Pharmaceuticals (NASDAQ VNDA) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.